Nephros Director Awarded 8,036 Shares in Compensation Grant
NEPHROS INC
Subscribe to track NEPH
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Nephros Director Awarded 8,036 Shares in Compensation Grant
Company: NEPHROS INC (NEPH) Form: 4 | Filed: 2025-11-13 Significance: Low
Insider: Spandow Oliver J. Title: null | Relationship: Director
Transaction: • Type: Grant • Shares: 8,036 • Price: $0.00 • Value: $0 • Owned After: 122,881
Key Insight: This is a routine stock award for a director, representing a negligible portion of the company's outstanding shares and having no immediate market value.
Market Context: For a small-cap company like Nephros ($50M market cap), equity compensation is a common way to align insider interests with shareholders. This grant has a minimal dilutive effect.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: NEPHROS INC (NEPH)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director received a routine, non-cash stock grant as part of their compensation package.
- Market Impact: Neutral. This type of transaction is standard and unlikely to influence the stock price.
Company Information
| Field | Value |
|---|---|
| Company | NEPHROS INC |
| Ticker Symbol | NEPH |
| CIK | 0001196298 |
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Insider Information
| Field | Value |
|---|---|
| Name | Spandow Oliver J. |
| CIK | 0001749836 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-10 |
| Transaction Code | A (Grant) |
| Security Type | Common Stock |
| Shares Involved | 8,036 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 122,881 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.0% |
| Shares Transacted | 8,036 |
| % of Shares Outstanding | 0.076% |
| Post-Transaction Ownership | 122,881 shares (1.16% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: Nephros is a small-cap company with a market capitalization of approximately $50 million. The transaction has no monetary value.
- Ownership Concentration: The director's ownership increases to approximately 1.16% of total shares outstanding, which is a modest holding.
- Dilution Impact: The grant represents less than 0.1% of shares outstanding, resulting in a negligible dilutive effect on existing shareholders.
- Transaction Significance: The transaction is classified as low significance as it is a non-cash award representing a very small fraction of the company's shares outstanding.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Stock grants are a standard form of non-cash compensation for directors and executives. As this transaction involved no open market activity and had a $0 value, it is not expected to have any impact on market sentiment or stock price.
Volume & Sentiment
- Expected Volume Impact: None. This was not an open-market transaction.
- Sentiment Indicator: Neutral. The filing is informational and reflects routine corporate governance.
Additional Context
Transaction Notes
- Special Circumstances: The transaction is a stock award (Code 'A') granted at a price of $0 per share, typical for compensation-related grants.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.